Cargando…

Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling

Thyroid cancer is one of the most common types of endocrine malignancy. In addition to surgical treatment, it is very important to find new treatment methods. The aim of the present study was to evaluate the effect of 1,3,8-trihydroxy-6-methylanthraquinone (emodin) on cellular NF-κB components and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xin, Wei, Wei, Wu, Yue-Zhang, Wang, Yuan, Zhang, Wei-Wei, Wang, Yong-Ping, Dong, Xiao-Ping, Shi, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623093/
https://www.ncbi.nlm.nih.gov/pubmed/37927413
http://dx.doi.org/10.3892/ol.2023.14101
_version_ 1785130674908299264
author Liu, Xin
Wei, Wei
Wu, Yue-Zhang
Wang, Yuan
Zhang, Wei-Wei
Wang, Yong-Ping
Dong, Xiao-Ping
Shi, Qi
author_facet Liu, Xin
Wei, Wei
Wu, Yue-Zhang
Wang, Yuan
Zhang, Wei-Wei
Wang, Yong-Ping
Dong, Xiao-Ping
Shi, Qi
author_sort Liu, Xin
collection PubMed
description Thyroid cancer is one of the most common types of endocrine malignancy. In addition to surgical treatment, it is very important to find new treatment methods. The aim of the present study was to evaluate the effect of 1,3,8-trihydroxy-6-methylanthraquinone (emodin) on cellular NF-κB components and the upstream regulatory pathway of toll-like receptor 4 (TLR4) signaling, as well as the invasion and migration of papillary thyroid carcinoma (PTC) cells. The protein expression of NF-κB components p65 and p50 and their phosphorylated (p-) forms in the sections of PTC tissues was measured by individual immunohistochemical assays. PTC cell lines TPC-1 and IHH4 were exposed to 20 and 40 µM emodin for 24 h. The levels of the NF-κB components p65, p50, c-Rel, p-p65 and p-p50, elements in TLR4 signaling, including TLR4, MYD88 innate immune signal transduction adaptor (MyD88), interferon regulatory factor 3, AKT and MEK, and proliferative and apoptotic biomarkers, including c-Myc, cyclin D1, proliferating cell nuclear antigen, Bcl-2 and Bax, were evaluated by western blotting and immunofluorescent assays. The invasion and migration of PTC cell lines exposed to emodin were tested by plate colony and wound healing assay. Compared with hyperplasia tissue, the expression levels of NF-κB components p65 and p50, and p-p65 and p-p50 in PTC tissue were significantly increased. Treatment of PTC cell lines with emodin lead to significantly reduced levels of the aforementioned NF-κB components, accompanied by markedly downregulated TLR4 signaling. MYD 88-dependent and -independent pathways, are also significantly down-regulated. Downregulation of proliferative factors and activation of apoptotic factors were observed in the cell lines following treatment with emodin. Consequently, inhibition of the invasion and migration activities were observed in the emodin-treated PTC cells. Emodin could inhibit proliferation and promote apoptosis of PTC cells, which is dependent on the downregulation of cellular NF-κB and the TLR4 signaling pathway.
format Online
Article
Text
id pubmed-10623093
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-106230932023-11-04 Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling Liu, Xin Wei, Wei Wu, Yue-Zhang Wang, Yuan Zhang, Wei-Wei Wang, Yong-Ping Dong, Xiao-Ping Shi, Qi Oncol Lett Articles Thyroid cancer is one of the most common types of endocrine malignancy. In addition to surgical treatment, it is very important to find new treatment methods. The aim of the present study was to evaluate the effect of 1,3,8-trihydroxy-6-methylanthraquinone (emodin) on cellular NF-κB components and the upstream regulatory pathway of toll-like receptor 4 (TLR4) signaling, as well as the invasion and migration of papillary thyroid carcinoma (PTC) cells. The protein expression of NF-κB components p65 and p50 and their phosphorylated (p-) forms in the sections of PTC tissues was measured by individual immunohistochemical assays. PTC cell lines TPC-1 and IHH4 were exposed to 20 and 40 µM emodin for 24 h. The levels of the NF-κB components p65, p50, c-Rel, p-p65 and p-p50, elements in TLR4 signaling, including TLR4, MYD88 innate immune signal transduction adaptor (MyD88), interferon regulatory factor 3, AKT and MEK, and proliferative and apoptotic biomarkers, including c-Myc, cyclin D1, proliferating cell nuclear antigen, Bcl-2 and Bax, were evaluated by western blotting and immunofluorescent assays. The invasion and migration of PTC cell lines exposed to emodin were tested by plate colony and wound healing assay. Compared with hyperplasia tissue, the expression levels of NF-κB components p65 and p50, and p-p65 and p-p50 in PTC tissue were significantly increased. Treatment of PTC cell lines with emodin lead to significantly reduced levels of the aforementioned NF-κB components, accompanied by markedly downregulated TLR4 signaling. MYD 88-dependent and -independent pathways, are also significantly down-regulated. Downregulation of proliferative factors and activation of apoptotic factors were observed in the cell lines following treatment with emodin. Consequently, inhibition of the invasion and migration activities were observed in the emodin-treated PTC cells. Emodin could inhibit proliferation and promote apoptosis of PTC cells, which is dependent on the downregulation of cellular NF-κB and the TLR4 signaling pathway. D.A. Spandidos 2023-10-13 /pmc/articles/PMC10623093/ /pubmed/37927413 http://dx.doi.org/10.3892/ol.2023.14101 Text en Copyright: © Liu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Liu, Xin
Wei, Wei
Wu, Yue-Zhang
Wang, Yuan
Zhang, Wei-Wei
Wang, Yong-Ping
Dong, Xiao-Ping
Shi, Qi
Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling
title Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling
title_full Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling
title_fullStr Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling
title_full_unstemmed Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling
title_short Emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of NF‑κB and its upstream TLR4 signaling
title_sort emodin treatment of papillary thyroid cancer cell lines in vitro inhibits proliferation and enhances apoptosis via downregulation of nf‑κb and its upstream tlr4 signaling
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623093/
https://www.ncbi.nlm.nih.gov/pubmed/37927413
http://dx.doi.org/10.3892/ol.2023.14101
work_keys_str_mv AT liuxin emodintreatmentofpapillarythyroidcancercelllinesinvitroinhibitsproliferationandenhancesapoptosisviadownregulationofnfkbanditsupstreamtlr4signaling
AT weiwei emodintreatmentofpapillarythyroidcancercelllinesinvitroinhibitsproliferationandenhancesapoptosisviadownregulationofnfkbanditsupstreamtlr4signaling
AT wuyuezhang emodintreatmentofpapillarythyroidcancercelllinesinvitroinhibitsproliferationandenhancesapoptosisviadownregulationofnfkbanditsupstreamtlr4signaling
AT wangyuan emodintreatmentofpapillarythyroidcancercelllinesinvitroinhibitsproliferationandenhancesapoptosisviadownregulationofnfkbanditsupstreamtlr4signaling
AT zhangweiwei emodintreatmentofpapillarythyroidcancercelllinesinvitroinhibitsproliferationandenhancesapoptosisviadownregulationofnfkbanditsupstreamtlr4signaling
AT wangyongping emodintreatmentofpapillarythyroidcancercelllinesinvitroinhibitsproliferationandenhancesapoptosisviadownregulationofnfkbanditsupstreamtlr4signaling
AT dongxiaoping emodintreatmentofpapillarythyroidcancercelllinesinvitroinhibitsproliferationandenhancesapoptosisviadownregulationofnfkbanditsupstreamtlr4signaling
AT shiqi emodintreatmentofpapillarythyroidcancercelllinesinvitroinhibitsproliferationandenhancesapoptosisviadownregulationofnfkbanditsupstreamtlr4signaling